Stay updated on Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page.

Latest updates to the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page
- Check7 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check14 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3; no substantive content changes to the study details are evident.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedNo significant changes detected on the Study Details page. The content and layout continue to present the trial design, eligibility, outcomes, and locations as before.SummaryDifference0.1%

- Check42 days agoChange DetectedMinor site maintenance updates were made: Revision: v3.4.2 was added and Revision: v3.4.1 was removed, along with a government operating status notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check49 days agoChange DetectedAdded a site-wide notice about possible delays due to a lapse in government funding with links to cc.nih.gov and opm.gov for status updates. Updated the site to revision v3.4.1, replacing v3.4.0.SummaryDifference0.4%

- Check56 days agoChange DetectedAdded a glossary feature and introduced the new Study Record Dates field 'Last Update Submitted that Met QC Criteria'. Standardized 'No FEAR Act' labeling and updated the page revision to v3.4.0.SummaryDifference0.2%

Stay in the know with updates to Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page.